Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

autoimmune disease

This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.

Checkpoint inhibitor scientists win Nobel Prize

Checkpoint inhibitor scientists win Nobel Prize

Allison was working on CTLA4 at the University of California, Berkeley, during the 1990s when much of the research on it was directed at ways to treat autoimmune disease.

Latest news

  • AstraZeneca’s Lupus treatment misses mark in trial AstraZeneca’s Lupus treatment misses mark in trial

    AstraZeneca’ s Lupus treatment misses mark in trial. Anifrolumab failed to show statistically significant reduction in disease activity. ... Sean Bohen, executive vice president, Global Medicines Development and chief medical officer, said: “SLE is a

  • Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

    Therapy related AML accounts for around 10% of all AMLs, and are caused by a patient's exposure to chemotherapy and/or radiation for a primary malignancy or autoimmune disease. ... Another variant of the disease, MPS IVa already has a treatment available

  • Roche’s MabThera ends drug drought for serious skin disease Roche’s MabThera ends drug drought for serious skin disease

    MabThera (rituximab) – an anti-CD20 antibody known as Rituxan in the US – has been cleared by the FDA for moderate to severe forms of the autoimmune disease, which causes painful blistering ... Rituximab already has a long list of approved

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    According to the company, Tavalisse targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing “an important new treatment option for adult patients with chronic ITP”. ... Rigel is also developing it for

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    No decision has yet been taken on other autoimmune disease indications for the drug, such as lupus, lupus nephritis, and Sjögren’s syndrome, according to analyst Hur Hye-min of Hi ... Celgene was developing a BTK inhibitor for autoimmune diseases

More from news
Approximately 3 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2)

    ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to

  • Reaching new heights Reaching new heights

    Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020

  • Pharma deals during May 2014 Pharma deals during May 2014

    Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of

  • The distressing impact of rare diseases The distressing impact of rare diseases

    The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Akari Therapeutics strengthens board Akari Therapeutics strengthens board

    His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    and commercialisation of orphan autoimmune and inflammatory disease treatments.

  • Caldan Therapeutics appoints CEO Caldan Therapeutics appoints CEO

    Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Patient Persepective: Autoimmune Disease

    Patient Persepective: Autoimmune Disease. Autoimmune diseases affect 1– 5% of the World’ s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including

  • Random42 Proud To Be Cannes Corporate Award Winners 2016

    Silver Winner - Random 42 for Systematic Lupus Erythematosus. This animation highlights the pathogenesis of Lupus, an autoimmune disease where the body’ s own immune system attacks healthy tissue.

  • Latest wave of Therapy Watch IBD to run this month

    A panel of 200 gastroenterologists will report in 10 IBD patient record forms each quarter (5 Crohn’ s disease and 5 ulcerative colitis), to monitor the evolving IBD treatment landscape.

More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Quick links

Infographics

Multimedia